Drug Search Results
More Filters [+]

Varlilumab

Alternative Names: varlilumab, cdx-1127, cdx1127, cdx 1127
Latest Update: 2024-05-08
Latest Update Note: Clinical Trial Update

Product Description

A human agonistic monoclonal antibody (MoAb) specific for CD27, with potential immunostimulating and antineoplastic activity. Upon administration of CDX-1127, this MoAb binds to CD27 and may potentiate the immune response by increasing the cytotoxic T-lymphocyte (CTL) response against CD27-expressing tumor cells. This may lead to growth inhibition of CD27-expressing tumor cells. In addition, this agent may increase the proliferation and activation of antigen-specific T lymphocytes upon co-administration of TAA-containing vaccines, such as dendritic cell vaccines. CD27, a co-stimulatory molecule and member of the tumor necrosis factor family overexpressed in certain tumor cell types, is constitutively expressed on mature T-lymphocytes, memory B cells and natural killer cells and plays an important role in NK cell mediated cytolytic activity and T and B lymphocyte proliferation and activation. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/varlilumab)

Mechanisms of Action: CD27 Agonist

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Celldex
Company Location: HAMPTON NJ 08827
Company CEO: Anthony S. Marucci
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Varlilumab

Countries in Clinic: United Kingdom, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 2: Glioblastoma|Lymphoma, B-Cell|Melanoma

Phase 1: Astrocytoma|Oligodendroglioma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

DERIVe

P2

Active, not recruiting

Glioblastoma

2025-03-01

Mel-65

P2

Completed

Melanoma

2024-01-19

NCI-2017-01369

P1

Active, not recruiting

Oligodendroglioma|Astrocytoma

2022-12-31

RiVa

P2

Active, not recruiting

Lymphoma, B-Cell

2021-02-18

Recent News Events